Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature

Samantha B J Schipper, Maaike M Van Veen, Petra J M Elders, Annemieke van Straten, Ysbrand D Van Der Werf, Kristen L Knutson, Femke Rutters, Samantha B J Schipper, Maaike M Van Veen, Petra J M Elders, Annemieke van Straten, Ysbrand D Van Der Werf, Kristen L Knutson, Femke Rutters

Abstract

Sleep disorders are linked to development of type 2 diabetes and increase the risk of developing diabetes complications. Treating sleep disorders might therefore play an important role in the prevention of diabetes progression. However, the detection and treatment of sleep disorders are not part of standardised care for people with type 2 diabetes. To highlight the importance of sleep disorders in people with type 2 diabetes, we provide a review of the literature on the prevalence of sleep disorders in type 2 diabetes and the association between sleep disorders and health outcomes, such as glycaemic control, microvascular and macrovascular complications, depression, mortality and quality of life. Additionally, we examine the extent to which treating sleep disorders in people with type 2 diabetes improves these health outcomes. We performed a literature search in PubMed from inception until January 2021, using search terms for sleep disorders, type 2 diabetes, prevalence, treatment and health outcomes. Both observational and experimental studies were included in the review. We found that insomnia (39% [95% CI 34, 44]), obstructive sleep apnoea (55-86%) and restless legs syndrome (8-45%) were more prevalent in people with type 2 diabetes, compared with the general population. No studies reported prevalence rates for circadian rhythm sleep-wake disorders, central disorders of hypersomnolence or parasomnias. Additionally, several cross-sectional and prospective studies showed that sleep disorders negatively affect health outcomes in at least one diabetes domain, especially glycaemic control. For example, insomnia is associated with increased HbA1c levels (2.51 mmol/mol [95% CI 1.1, 4.4]; 0.23% [95% CI 0.1, 0.4]). Finally, randomised controlled trials that investigate the effect of treating sleep disorders in people with type 2 diabetes are scarce, based on a small number of participants and sometimes inconclusive. Conventional therapies such as weight loss, sleep education and cognitive behavioural therapy seem to be effective in improving sleep and health outcomes in people with type 2 diabetes. We conclude that sleep disorders are highly prevalent in people with type 2 diabetes, negatively affecting health outcomes. Since treatment of the sleep disorder could prevent diabetes progression, efforts should be made to diagnose and treat sleep disorders in type 2 diabetes in order to ultimately improve health and therefore quality of life.

Keywords: Health outcomes; Prevalence; Review; Sleep disorders; Type 2 diabetes.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Summary of the literature to date on association between sleep disorders, health outcomes and QoL in people with type 2 diabetes. ↑, increased risk or higher levels; ↓, decreased risk or lower levels; =, no change in risk or levels; ?, no data available. Bold black arrows, strong evidence based on large study sample or multiple studies; non-bold black arrows, medium strength evidence; grey arrows, evidence based on small sample or subgroup. This figure is available as part of a downloadable slideset
Fig. 2
Fig. 2
Summary of the possible pharmacological and non-pharmacological treatment options for sleep disorders in people with type 2 diabetes. Bold text, strong evidence based on large study sample or multiple studies; non-bold black text, medium strength evidence; grey text, evidence based on small study sample or subgroup. This figure is available as part of a downloadable slideset

References

    1. Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: systematic review and meta-analysis. Sleep Med Rev. 2016;30:11–24. doi: 10.1016/j.smrv.2015.10.002.
    1. Yuan S, Larsson SC. An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study. Diabetologia. 2020;63(11):2359–2371. doi: 10.1007/s00125-020-05253-x.
    1. American Academy of Sleep Medicine (2014) International classification of sleep medicine, 3rd edn. American Academy of Sleep Medicine, Darien, IL
    1. Mohammadi S, Dolatshahi M, Zare-Shahabadi A, Rahmani F. Untangling narcolepsy and diabetes: pathomechanisms with eyes on therapeutic options. Brain Res. 2019;1718:212–222. doi: 10.1016/j.brainres.2019.04.013.
    1. Weng N, Luo YW, Xu JD, Zhang Y. Abnormal nocturnal behavior due to hypoglycemia: a case report. Medicine. 2019;98(6):e14405. doi: 10.1097/md.0000000000014405.
    1. Wong JC, Li J, Pavlova M, et al. Risk factors for probable REM sleep behavior disorder: a community-based study. Neurology. 2016;86(14):1306–1312. doi: 10.1212/wnl.0000000000002414.
    1. Martynowicz H, Gac P, Brzecka A, et al. The relationship between sleep bruxism and obstructive sleep apnea based on polysomnographic findings. J Clin Med. 2019;8(10):1653. doi: 10.3390/jcm8101653.
    1. Sweetman A, Melaku YA, Lack L, et al. Prevalence and associations of co-morbid insomnia and sleep apnoea in an Australian population-based sample. Sleep Med. 2021;82:9–17. doi: 10.1016/j.sleep.2021.03.023.
    1. Koopman ADM, Beulens JW, Dijkstra T, et al. Prevalence of insomnia (symptoms) in T2D and association with metabolic parameters and glycemic control: meta-analysis. J Clin Endocrinol Metab. 2020;105(3):614–643. doi: 10.1210/clinem/dgz065.
    1. Chew M, Tan NYQ, Lamoureux E, Cheng C-Y, Wong TY, Sabanayagam C. The associations of objectively measured sleep duration and sleep disturbances with diabetic retinopathy. Diabetes Res Clin Pract. 2020;159:107967. doi: 10.1016/j.diabres.2019.107967.
    1. Nefs G, Donga E, van Someren E, Bot M, Speight J, Pouwer F. Subjective sleep impairment in adults with type 1 or type 2 diabetes: results from diabetes MILES—the Netherlands. Diabetes Res Clin Pract. 2015;109(3):466–475. doi: 10.1016/j.diabres.2015.07.008.
    1. Vgontzas AN, Liao D, Pejovic S, et al. Insomnia with short sleep duration and mortality: the Penn State cohort. Sleep. 2010;33(9):1159–1164. doi: 10.1093/sleep/33.9.1159.
    1. Jain A, Sharmab R, Yadavc N, Chaudhary P, Jainc G, Maanju M. Quality of life and its association with insomnia and clinical variables in type 2 diabetes. J Egypt Public Health Assoc. 2017;92(1):52–59. doi: 10.21608/epx.2018.7011.
    1. Lou P, Qin Y, Zhang P, et al. Association of sleep quality and quality of life in type 2 diabetes mellitus: a cross-sectional study in China. Diabetes Res Clin Pract. 2015;107(1):69–76. doi: 10.1016/j.diabres.2014.09.060.
    1. Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. Chest. 2017;152(5):1070–1086. doi: 10.1016/j.chest.2017.05.009.
    1. Kent BD, McNicholas WT, Ryan S. Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea. J Thorac Dis. 2015;7(8):1343–1357. doi: 10.3978/j.issn.2072-1439.2015.08.11.
    1. Grimaldi D, Beccuti G, Touma C, Van Cauter E, Mokhlesi B. Association of obstructive sleep apnea in rapid eye movement sleep with reduced glycemic control in type 2 diabetes: therapeutic implications. Diabetes Care. 2014;37(2):355–363. doi: 10.2337/dc13-0933.
    1. West SD, Groves DC, Lipinski HJ, et al. The prevalence of retinopathy in men with type 2 diabetes and obstructive sleep apnoea. Diabet Med. 2010;27(4):423–430. doi: 10.1111/j.1464-5491.2010.02962.x.
    1. Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic nephropathy: a cohort study. Diabetes Care. 2013;36(11):3718–3725. doi: 10.2337/dc13-0450.
    1. Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012;186(5):434–441. doi: 10.1164/rccm.201112-2135OC.
    1. Seicean S, Strohl KP, Seicean A, Gibby C, Marwick TH. Sleep disordered breathing as a risk of cardiac events in subjects with diabetes mellitus and normal exercise echocardiographic findings. Am J Cardiol. 2013;111(8):1214–1220. doi: 10.1016/j.amjcard.2012.12.053.
    1. Labarca G, Dreyse J, Salas C et al (2021) Risk of mortality among patients with moderate to severe obstructive sleep apnea and diabetes mellitus: results from the SantOSA cohort. Sleep Breath. 10.1007/s11325-020-02283-y
    1. Gabric K, Matetic A, Vilovic M, et al. Health-related quality of life in type 2 diabetes mellitus patients with different risk for obstructive sleep apnea. Patient Prefer Adherence. 2018;12:765–773. doi: 10.2147/PPA.S165203.
    1. Panossian LA, Avidan AY. Review of sleep disorders. Med Clin N Am. 2009;93(2):407–425. doi: 10.1016/j.mcna.2008.09.001.
    1. Cho YW, Na GY, Lim JG, et al. Prevalence and clinical characteristics of restless legs syndrome in diabetic peripheral neuropathy: comparison with chronic osteoarthritis. Sleep Med. 2013;14(12):1387–1392. doi: 10.1016/j.sleep.2013.09.013.
    1. Cuellar NG, Ratcliffe SJ. A comparison of glycemic control, sleep, fatigue, and depression in type 2 diabetes with and without restless legs syndrome. J Clin Sleep Med. 2008;4(1):50–56. doi: 10.5664/jcsm.27079.
    1. Harashima S, Nishimura A, Osugi T, et al. Restless legs syndrome in patients with type 2 diabetes: effectiveness of pramipexole therapy. BMJ Support Palliat Care. 2016;6(1):89–93. doi: 10.1136/bmjspcare-2014-000691.
    1. Lopes LA, Lins Cde M, Adeodato VG, et al. Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care. 2005;28(11):2633–2636. doi: 10.2337/diacare.28.11.2633.
    1. Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep. 2007;30(7):866–871. doi: 10.1093/sleep/30.7.866.
    1. Modarresnia L, Golgiri F, Madani NH, Emami Z, Tanha K. Restless legs syndrome in Iranian people with type 2 diabetes mellitus: the role in quality of life and quality of sleep. J Clin Sleep Med. 2018;14(2):223–228. doi: 10.5664/jcsm.6938.
    1. Skomro RP, Ludwig S, Salamon E, Kryger MH. Sleep complaints and restless legs syndrome in adult type 2 diabetics. Sleep Med. 2001;2(5):417–422. doi: 10.1016/s1389-9457(01)00110-1.
    1. Zobeiri M, Shokoohi A. Restless leg syndrome in diabetics compared with normal controls. Sleep Disord. 2014;2014:871751. doi: 10.1155/2014/871751.
    1. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–873. doi: 10.1016/j.sleep.2014.03.025.
    1. Bener A, Al-Hamaq AOAA, Ağan AF, Öztürk M, Ömer A. The prevalence of restless legs syndrome and comorbid condition among patient with type 2 diabetic mellitus visiting primary healthcare. J Family Med Prim Care. 2019;8(12):3814–3820. doi: 10.4103/jfmpc.jfmpc_463_19.
    1. Merlino G, Valente M, Serafini A, et al. Effects of restless legs syndrome on quality of life and psychological status in patients with type 2 diabetes. Diabetes Educ. 2010;36(1):79–87. doi: 10.1177/0145721709351252.
    1. Rizzi M, Barrella M, Kotzalidis GD, Bevilacqua M. Periodic limbic movement disorder during sleep as diabetes-related syndrome? A polysomnographic study. ISRN Endocrinol. 2011;2011:246157. doi: 10.5402/2011/246157.
    1. Stenvers DJ, Scheer F, Schrauwen P, la Fleur SE, Kalsbeek A. Circadian clocks and insulin resistance. Nat Rev Endocrinol. 2019;15(2):75–89. doi: 10.1038/s41574-018-0122-1.
    1. Chalernvanichakorn T, Sithisarankul P, Hiransuthikul N. Shift work and type 2 diabetic patients' health. J Med Assoc Thail. 2008;91(7):1093–1096.
    1. El Tayeb IM, El Saghier EOA, Ramadan BK. Impact of shift work on glycemic control in insulin treated diabetics Dar El Chefa Hospital, Egypt 2014. Int J Diabetes Res. 2014;3(2):15–21. doi: 10.5923/j.diabetes.20140302.02.
    1. Manodpitipong A, Saetung S, Nimitphong H, et al. Night-shift work is associated with poorer glycaemic control in patients with type 2 diabetes. J Sleep Res. 2017;26(6):764–772. doi: 10.1111/jsr.12554.
    1. Jørgensen JT, Karlsen S, Stayner L, Hansen J, Andersen ZJ. Shift work and overall and cause-specific mortality in the Danish nurse cohort. Scand J Work Environ Health. 2017;43(2):117–126. doi: 10.5271/sjweh.3612.
    1. Abad VC, Guilleminault C. Diagnosis and treatment of sleep disorders: a brief review for clinicians. Dialogues Clin Neurosci. 2003;5(4):371–388. doi: 10.31887/DCNS.2003.5.4/vabad.
    1. Yoshikawa F, Shigiyama F, Ando Y, et al. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia. Diabetes Res Clin Pract. 2020;169:108412. doi: 10.1016/j.diabres.2020.108412.
    1. Kothari V, Cardona Z, Chirakalwasan N, Anothaisintawee T, Reutrakul S. Sleep interventions and glucose metabolism: systematic review and meta-analysis. Sleep Med. 2021;78:24–35. doi: 10.1016/j.sleep.2020.11.035.
    1. Mast R, Rauh SP, Groeneveld L, et al. The use of antidepressants, anxiolytics, and hypnotics in people with type 2 diabetes and patterns associated with use: the Hoorn Diabetes Care System Cohort. Biomed Res Int. 2017;2017:5134602. doi: 10.1155/2017/5134602.
    1. Kamphuis J, Taxis K, Schuiling-Veninga CC, Bruggeman R, Lancel M. Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in the Netherlands. J Clin Psychopharmacol. 2015;35(4):468–470. doi: 10.1097/jcp.0000000000000338.
    1. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700. doi: 10.1111/jsr.12594.
    1. Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307–313. doi: 10.2147/dmso.S23904.
    1. Tsunoda T, Yamada M, Akiyama T, et al. The effects of ramelteon on glucose metabolism and sleep quality in type 2 diabetic patients with insomnia: a pilot prospective randomized controlled trial. J Clin Med Res. 2016;8(12):878–887. doi: 10.14740/jocmr2754w.
    1. Doosti-Irani A, Ostadmohammadi V, Mirhosseini N, et al. The effects of melatonin supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Horm Metab Res. 2018;50(11):783–790. doi: 10.1055/a-0752-8462.
    1. Lyssenko V, Nagorny CLF, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–88. doi: 10.1038/ng.288.
    1. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039–1062. doi: 10.5665/sleep.1988.
    1. Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 2011;12(1):34–40. doi: 10.1016/j.sleep.2010.08.005.
    1. Kwatra V, Khan MA, Quadri SA, Cook TS. Differential diagnosis and treatment of restless legs syndrome: a literature review. Cureus. 2018;10(9):e3297–e3297. doi: 10.7759/cureus.3297.
    1. Martínez-Cerón E, Barquiel B, Bezos AM, et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes. A randomized clinical trial. Am J Respir Crit Care Med. 2016;194(4):476–485. doi: 10.1164/rccm.201510-1942OC.
    1. Labarca G, Reyes T, Jorquera J, Dreyse J, Drake L. CPAP in patients with obstructive sleep apnea and type 2 diabetes mellitus: systematic review and meta-analysis. Clin Respir J. 2018;12(8):2361–2368. doi: 10.1111/crj.12915.
    1. Yang X, Yang J, Yang C, Niu L, Song F, Wang L. Continuous positive airway pressure can improve depression in patients with obstructive sleep apnoea syndrome: a meta-analysis based on randomized controlled trials. J Int Med Res. 2020;48(3):300060519895096. doi: 10.1177/0300060519895096.
    1. Baslas V, Chand P, Jurel SK, et al. A pilot study to determine the effect of three months of oral appliance therapy using a mandibular advancement device on HbA1c in subjects with type 2 diabetes mellitus and obstructive sleep apnea. J Prosthodont. 2019;28(3):271–275. doi: 10.1111/jopr.12973.
    1. Schwartz M, Acosta L, Hung YL, Padilla M, Enciso R. Effects of CPAP and mandibular advancement device treatment in obstructive sleep apnea patients: a systematic review and meta-analysis. Sleep Breath. 2018;22(3):555–568. doi: 10.1007/s11325-017-1590-6.
    1. Kuna ST, Reboussin DM, Strotmeyer ES, et al. Effects of weight loss on obstructive sleep apnea severity. ten-year results of the sleep AHEAD study. Am J Respir Crit Care Med. 2021;203(2):221–229. doi: 10.1164/rccm.201912-2511OC.
    1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. Jama. 2004;292(14):1724–1737. doi: 10.1001/jama.292.14.1724.
    1. Tang Y, Sun Q, Bai XY, Zhou YF, Zhou QL, Zhang M. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Nutr Diabetes. 2019;9(1):32. doi: 10.1038/s41387-019-0098-5.
    1. Tannas CL, Davis JE (2013) Type 2 diabetes and insomnia: impact on metabolic control. Wayne State University Dissertations. Paper 624.
    1. Alshehri MM, Alothman SA, Alenazi AM, et al. The effects of cognitive behavioral therapy for insomnia in people with type 2 diabetes mellitus, pilot RCT part II: diabetes health outcomes. BMC Endocr Disord. 2020;20(1):136. doi: 10.1186/s12902-020-00612-6.
    1. Alshehri MM, Alenazi AM, Alothman SA, et al. Using cognitive behavioral therapy for insomnia in people with type 2 diabetes, pilot RCT part I: sleep and concomitant symptom. Behav Sleep Med. 2020;27:1–20. doi: 10.1080/15402002.2020.1831501.
    1. Blom K, Jernelöv S, Rück C, Lindefors N, Kaldo V. Three-year follow-up comparing cognitive behavioral therapy for depression to cognitive behavioral therapy for insomnia, for patients with both diagnoses. Sleep. 2017;40(8):1–5. doi: 10.1093/sleep/zsx108.
    1. Li M, Li D, Tang Y, et al. Effect of diabetes sleep education for T2DM who sleep after midnight: a pilot study from China. Metab Syndr Relat Disord. 2018;16(1):13–19. doi: 10.1089/met.2017.0069.
    1. Pereira FH, Trevisan DD, Santos Lourenço D, da Silva JB, Lima MHM. Effect of educational strategies on the sleep quality of people with diabetes: randomized clinical trial. Aquichan. 2019;19(3):1–13. doi: 10.5294/aqui.2019.19.3.2.
    1. Yoon JM, Cho E-G, Lee H-K, Park SM. Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J Fam Med. 2013;34(4):228–240. doi: 10.4082/kjfm.2013.34.4.228.
    1. Brouwer A, van Raalte DH, Nguyen HT, et al. Effects of light therapy on mood and insulin sensitivity in patients with type 2 diabetes and depression: results from a randomized placebo-controlled trial. Diabetes Care. 2019;42(4):529–538. doi: 10.2337/dc18-1732.
    1. Reutrakul S, Van Cauter E. Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. Ann N Y Acad Sci. 2014;1311:151–173. doi: 10.1111/nyas.12355.
    1. Chasens ER, Korytkowski M, Sereika SM, Burke LE. Effect of poor sleep quality and excessive daytime sleepiness on factors associated with diabetes self-management. Diabetes Educ. 2013;39(1):74–82. doi: 10.1177/0145721712467683.
    1. Larcher S, Benhamou PY, Pépin JL, Borel AL. Sleep habits and diabetes. Diabetes Metab. 2015;41(4):263–271. doi: 10.1016/j.diabet.2014.12.004.
    1. Lamond N, Tiggemann M, Dawson D. Factors predicting sleep disruption in type II diabetes. Sleep. 2000;23(3):415–416. doi: 10.1093/sleep/23.3.1i.
    1. eHealthMe (2021). Metformin and Insomnia concerns - a phase IV clinical study of FDA data. Available from . Accessed 12 May 2021
    1. Lecube A, Romero O, Sampol G, et al. Sleep biosignature of type 2 diabetes: a case-control study. Diabet Med. 2017;34(1):79–85. doi: 10.1111/dme.13161.
    1. Pallayova M, Donic V, Gresova S, Peregrim I, Tomori Z. Do differences in sleep architecture exist between persons with type 2 diabetes and nondiabetic controls? J Diabetes Sci Technol. 2010;4(2):344–352. doi: 10.1177/193229681000400215.
    1. American Diabetes Association Lifestyle management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S46–S60. doi: 10.2337/dc19-S005.
    1. de Groot R (2018) Alles over slaap. Available from . Accessed 10 January 2021 [presentation in Dutch]

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe